Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) EBITDA Margin (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of EBITDA Margin data on record, last reported at 480.94% in Q4 2025.

  • For Q4 2025, EBITDA Margin fell 40476.0% year-over-year to 480.94%; the TTM value through Dec 2025 reached 4.86%, up 7866.0%, while the annual FY2025 figure was 8.45%, 4596.0% up from the prior year.
  • EBITDA Margin reached 480.94% in Q4 2025 per PTCT's latest filing, down from 10.94% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 82.5% in Q1 2025 and bottomed at 480.94% in Q4 2025.
  • Average EBITDA Margin over 5 years is 65.81%, with a median of 54.58% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: soared 16449bps in 2021, then crashed -40476bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 51.28% in 2021, then tumbled by -133bps to 119.67% in 2022, then surged by 102bps to 1.9% in 2023, then tumbled by -4119bps to 76.18% in 2024, then plummeted by -531bps to 480.94% in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 480.94% in Q4 2025, 10.94% in Q3 2025, and 39.72% in Q2 2025.